Rightslink® by Copyright Clearance Center

First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience

Author:

G. Jeryczynski,M. Antlanger,F. Duca,C. Binder-Rodriguez,T. Reiter,I. Simonitsch-Klupp,D. Bonderman,R. Kain,M.-T. Krauth,H. Agis

Publication:

Esmo Open

Publisher:

Elsevier

Date:

April 2021

Please select your organization and/or account

Organization

Account

Please select your account from the above dropdown list. These accounts represent the offices, campuses, and other sites where your organization operates. Your account selection should match where you typically have an office or workspace. Even when you are traveling or temporarily working elsewhere, you should select the account that represents where you customarily work.

Cancel OK

Welcome to RightsLink

Elsevier has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing this content.

I would like to...This drop down menu contains the options the publisher has agreed to permit for reuse of their copyrighted material. The publisher offers these types of use either directly through RightsLink or after approval by the publisher. Please reference the terms and conditions offered during the order process for a complete understanding of the use you select. Need more info?

To request permission for a type of use not listed, please contact Elsevier Global Rights Department.

Are you the author of this Elsevier journal article?